Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity.
carcinoma
molecular pathology
molecular targeted therapy
non-small cell lung
precision medicine
predictive tumor markers
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
14
10
2019
accepted:
17
12
2019
entrez:
11
2
2020
pubmed:
11
2
2020
medline:
11
2
2020
Statut:
epublish
Résumé
The diagnostic landscape of non-small cell lung cancer (NSCLC) is changing rapidly with the availability of novel treatments. Despite high-level healthcare in the Netherlands, not all patients with NSCLC are tested with the currently relevant predictive tumor markers that are necessary for optimal decision-making for today's available targeted or immunotherapy. An expert workshop on the molecular diagnosis of NSCLC involving pulmonary oncologists, clinical chemists, pathologists, and clinical scientists in molecular pathology was held in the Netherlands on December 10, 2018. The aims of the workshop were to facilitate cross-disciplinary discussions regarding standards of practice, and address recent developments and associated challenges that impact future practice. This paper presents a summary of the discussions and consensus opinions of the workshop participants on the initial challenges of harmonization of the detection and clinical use of predictive markers of NSCLC. A key theme identified was the need for broader and active participation of all stakeholders involved in molecular diagnostic services for NSCLC, including healthcare professionals across all disciplines, the hospitals and clinics involved in service delivery, healthcare insurers, and industry groups involved in diagnostic and treatment innovations. Such collaboration is essential to integrate different technologies into molecular diagnostics practice, to increase nationwide patient access to novel technologies, and to ensure consensus-preferred biomarkers are tested.
Identifiants
pubmed: 32039011
doi: 10.3389/fonc.2019.01521
pmc: PMC6987414
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1521Informations de copyright
Copyright © 2020 van den Broek, Hiltermann, Biesma, Dinjens, 't Hart, Hinrichs, Leers, Monkhorst, van Oosterhout, Scharnhorst, Schuuring, Speel, van den Heuvel, van Schaik, von der Thüsen, Willems, de Visser and Ligtenberg.
Références
JAMA Oncol. 2018 Apr 1;4(4):569-570
pubmed: 29494728
BMC Cancer. 2018 Mar 9;18(1):269
pubmed: 29523116
J Natl Cancer Inst. 2019 Jun 1;111(6):575-583
pubmed: 30496436
J Clin Pathol. 2013 Oct;66(10):870-4
pubmed: 23801495
J Thorac Oncol. 2013 Jun;8(6):773-8
pubmed: 23575414
Eur J Cancer. 2017 Aug;81:66-73
pubmed: 28609695
Curr Treat Options Oncol. 2018 Sep 29;19(11):58
pubmed: 30267319
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Clin Med. 2018 Jun 29;7(7):
pubmed: 29966246
JAMA Oncol. 2017 Aug 1;3(8):1051-1058
pubmed: 28278348
Transl Lung Cancer Res. 2017 Oct;6(5):560-569
pubmed: 29114472
Nat Rev Clin Oncol. 2018 Sep;15(9):577-586
pubmed: 29968853
Cancer Sci. 2016 Nov;107(11):1660-1666
pubmed: 27575703
Virchows Arch. 2017 Jan;470(1):5-20
pubmed: 27678269
Oncologist. 2016 Sep;21(9):1121-30
pubmed: 27388233
Int J Cancer. 2019 Aug 1;145(3):649-661
pubmed: 30653256
J Thorac Oncol. 2017 Feb;12(2):208-222
pubmed: 27913228
Expert Rev Mol Diagn. 2015;15(8):1061-74
pubmed: 26153330
Ned Tijdschr Geneeskd. 2018 Dec 5;162:
pubmed: 30570921
J Natl Compr Canc Netw. 2018 Jul;16(7):807-821
pubmed: 30006423
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S275-S279
pubmed: 30393621
J Natl Cancer Inst. 2014 Sep 12;106(10):
pubmed: 25217578
Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):593-599
pubmed: 30052095
Oncotarget. 2016 Apr 12;7(15):19738-47
pubmed: 26918451
Front Oncol. 2019 Mar 05;9:129
pubmed: 30891428
J Thorac Oncol. 2012 Mar;7(3):496-502
pubmed: 22246194
Nat Rev Genet. 2019 Feb;20(2):71-88
pubmed: 30410101
J Clin Oncol. 2016 Oct 1;34(28):3375-82
pubmed: 27354477
J Clin Oncol. 2018 Jun 1;36(16):1631-1641
pubmed: 29504847
Clin Cancer Res. 2019 Aug 1;25(15):4691-4700
pubmed: 30988079
Mod Pathol. 2019 Jan;32(Suppl 1):16-26
pubmed: 30600321
Lung Cancer. 2018 Feb;116:90-95
pubmed: 29413057
Br J Cancer. 2018 Aug;119(5):605-614
pubmed: 30140047
Curr Oncol Rep. 2018 Jul 20;20(9):70
pubmed: 30030656
Comput Struct Biotechnol J. 2018 Oct 09;16:370-378
pubmed: 30364656
Arch Pathol Lab Med. 2018 Mar;142(3):353-357
pubmed: 29219616
Br J Cancer. 2014 Jul 15;111(2):413-20
pubmed: 24983368
Virchows Arch. 2019 Jun;474(6):681-689
pubmed: 31028539
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Value Health. 2016 Jul-Aug;19(5):577-87
pubmed: 27565275
J Thorac Oncol. 2018 Mar;13(3):323-358
pubmed: 29396253
Am Soc Clin Oncol Educ Book. 2018 May 23;38:708-715
pubmed: 30231309
J Thorac Oncol. 2018 Sep;13(9):1302-1311
pubmed: 29800747
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Oncotarget. 2018 Apr 17;9(29):20524-20538
pubmed: 29755669
Ther Drug Monit. 2019 Apr;41(2):115-120
pubmed: 30883505
J Thorac Oncol. 2016 May;11(5):613-638
pubmed: 27013409
Cancer Epidemiol. 2017 Dec;51:1-6
pubmed: 28963913
J Thorac Dis. 2018 Sep;10(9):5468-5475
pubmed: 30416796
Thorax. 2016 Feb;71(2):177-84
pubmed: 26530085
J Cancer Res Clin Oncol. 2016 Jun;142(6):1353-60
pubmed: 26995276
J Hematol Oncol. 2017 Oct 23;10(1):167
pubmed: 29061113
JAMA Oncol. 2019 Feb 1;5(2):173-180
pubmed: 30325992
BMC Cancer. 2016 Feb 06;16:66
pubmed: 26851938
J Vasc Interv Radiol. 2018 Nov;29(11):1535-1541.e2
pubmed: 30293735
Eur J Surg Oncol. 2013 Nov;39(11):1199-206
pubmed: 24044806
Clin Cancer Res. 2017 Jul 15;23(14):3585-3591
pubmed: 28073845
BMC Cancer. 2018 Aug 9;18(1):804
pubmed: 30092778
Int J Cancer. 2016 Jun 1;138(11):2549-61
pubmed: 26537995
PLoS Med. 2017 Feb 14;14(2):e1002230
pubmed: 28196074
Ann Transl Med. 2018 Apr;6(8):138
pubmed: 29862227